Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma
To assess the efficacy of an Angiotensin-II inhibitor (Losartan) to reduce peritumoral edema in newly diagnosed glioblastoma patients.
Newly-diagnosed Glioblastoma
DRUG: Losartan|DRUG: Placebo
Steroid dosage required to control brain edema on the last day of radiotherapy in each arm, Up to Day 42+ 1 month
Steroids dosage 1 month after the end of RT, Day 42+ 1 month|Assessment of cerebral edema on MRI, Day -28 at -13, Day 42, Day 42+1 month|Tolerance (NCI-CTCAE v3.0), To be reported according to NCI/CTC version 3.0 (adverse events), up to day42 +1 month + 7 days|Blood pressure, Day -10 at -7, Day0, 42, Day 42+1month|HbA1C, Day -10 at -7, D42, Day 42+1month|glycemia, Day -10 at -7, Day14, 28, 42, Day 42+1month|body weight, Day -10 at -7, Day42, Day 42+1month|side-effects of steroids, up to day42 +1 month|Executive functions ( " Moca test "), Day-10 at -7, Day 42, Day 42+1 month|Quality of life (EORTC), Day-10 at -7, Day 42, Day 42+1 month|Progression free survival, up to 24 months|Overall survival, up to 24 months|Survival, at 1 year, 2 year|Performance status (KPS) at the end, 1 month , and 2 months after the end of RT, at the end, 1 month, and 2 months after the end of RT
Multicentre, randomized (1:1), double blinded trial:- Arm A: Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide ) + Losartan 50mg\*2/day until the halting for any reason - Arm B: Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the halting for any reason.